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The journey from tech transfer to BLA submission: case study of a 
NS0 cell culture process from 2000L Stainless steel bioreactor to 
2000L disposable bioreactor
Jincai Li, PhD
Drug Substance Manufacturing (MFG1), WuXi Biologics, Wuxi, China. (li_jincai@wuxiapptec.com)
Growth challenges in 2D bags during process  
transfer (from 2000L stainless steel bioreactor to 
2000L SUBs)
Process Characterization & PPQ campaign
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Abstract
A case study of NS0 cell culture process transfer 
from 2000L stainless steel bioreactor (SST) to 2000L 
disposable bioreactor (SUB), and through to process 
validation and BLA submission is reported for production 
of an antibody therapeutics in this poster. Initial attempts 
in growing the NS0 cells in the small scale 2D bags 
yielded non-satisfactory results, as growth was impacted 
by bag material type as well as by different suppliers of 
the same bag material type. However, 3D bags of 50L 
and above proved to be supportive of the NS0 cell line 
growth. 
Process characterization (PC) and process 
validation (PV) efforts were initiated after successful 
scale up to the 2000L SUB. Scale down model (3L) was 
qualified using bench top glass bioreactors, and PC 
studies identified several critical process parameters 
(CPPs). Successful process performance qualification 
(PPQ) campaign followed and BLA was submitted in 
2017.
Leachables & extractables on SUBs
 Concern on L&E for cell culture is one of the main 
challenges for SUB implementation 
 Impact of L&E for cell culture
 Patient safety: toxic effects on patients
 Process impact: cell culture performance impacts
Scale down models for 2000L SUBs
•The author would like to thank members of the project team, the 
process development group, manufacturing organizations at WuXi 
Biologics for the contributions
•We would also like to thank the client for the collaborations
Study 
name
Study conditions
Bag A- 1 Direct culture in Hyclone 2D 
bag
Bag A- 2 Media incubation @ 37C, 
48hr;  then  inoc to SF
Bag A- 3 Media  w/o cholesterol & 
insulin incubated @ 37C, 
48hr;  then add chol & 
insulin back;  inoc to SF
Bag A- 4 Water w/ 1x chol incubated
@ 37C, 48hr; then used to 
prep medium and inoc to 
SF
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and insulin incubated at 37℃
for 48h in bag, and  Add C& I 
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Water  with 1×cholesterol 
incubated in bag at 37℃ for 
48 h, then use the water to 
prepare T100 medium
Step 2
Step 3
Step 4
B
ag A
 (U
LD
P
E)
2
D
 b
ag
Medium incubated in bags at 
37℃ for 48h; then inoc to SF
Challenges in growing NS0 cells in disposable bags
Some disposable 
bags do support 
growth
• Different bags have different materials & are made with
different processes
• Even bags with same contact layer material had different 
impact on growth
• Other materials, e.g., additives, could have major impact
• Ex: Thermo’s Aegis 5-14 film vs CX 5-14
• Suppliers might switch films
• Ex: Sartorius Flexsafe S80 film replacing earlier S40 film
Not all bags are the same
• Various attempts using vendor A 2D bags did not lead to satisfactory 
results
• The fact that other bags w/ the same ULDPE material supported 
growth was encouraging
• 2D bag might not be a good scale-down model of 3D & large volume 
bags
• Surface to volume ratio much larger
• If there are leachables, 2D bag would be worst case scenario
• Two options
• Try vendor A 50L SUB to see if growth is OK
• Try vendor B SUB 
Satisfactory results from 50L SUB 
• Culture performance in 50L SUB was 
comparable to 3L glass vessel and 
historical GMP data
• Indeed 2D bag was not a good scale-
down model
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1st 50L SUB showed good performance
• 250L SUB as last step before scaling up to 2000L SUB
• Process designed to mimic 2000L operation as much as possible
• Good performance at 250L SUB, with full analytical comparability 
assessment
• Cleared to scale-up to 2000L SUB
Process confirmation at 250L SUB
 Successful scale-up to 2000L SUB
• Growth & productivity at 
2000L SUB (eng run & GMP 
run) matched very well with 
historical GMP data
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Productivity comparison between different scales
Unexpected challenge in glycosylation profiles
• Satellite cultures of 2000L SUB had 
dramatic difference in glycosylation
profiles
• One matched 2000L SUB well
• The other had significant 
differences
• Other performance indicators were 
comparable, e.g., titer, growth etc
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Unexpected challenge in scale-down model transfer
• Significant differences in glycan profiles among different small 
scale cultures
• Difference between 1L vs 3L model
• Even among 3L bioreactors, difference remained
• Glass vessel had same dimensions
• Agitator  diameter different
• Sparger different
• Baffle presence or not  also made a difference
 Need to be careful in picking the right scale-down model!
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Successful scale down model verification
• Four CPPs identified:  N-1 culture & production culture 
medium concentration; culture temp; culture pH; 1st feed 
glucose & VCC level
• NOR (normal operation range) of the CPPs defined through 
DoE studies; MOR (max operation range) defined through 
univariate studies
• Control strategies defined based on development & PC 
studies
BLA submission
Disposable Bag Contact Layer
Thermo SUB ULDPE
Thermo Container Bag ULDPE
WAVE Bag EVA
Sartorius RM/Flexboy Bag EVA
Sartorius STR CultiBag ULDPE
Sartorius Flexsafe Bag (RM/STR etc) LLDPE
GE Xcellerex Bag ULDPE
Shake Flask PC
Millipore Container Bag ULDPE
Lack of good scale down models for SUBs
 None of the major suppliers of SUBs offer representative 
scale-down models of the larger scale SUBs
 50L SUBs appear to be the most appropriate models to 
represent 2000L scales.  But it is too expensive to be an 
economical model. Surface/volume ratio worse than 2000L 
 Benchtop glass bioreactors are still being widely used as 
scale-down models for large scale SUBs.
 However, leachables & extratables can not be tested with 
glass bioreactors.  Product quality impact from SUBs also 
can not be evaluated with glass bioreactors 
Background: NS0 cell line with chemically-defined medium
Medium contains insulin & cholesterol
Robust process demonstrated by 2000L SST GMP runs
 Objective: transfer & scale-up to 2000L SUB for PhIII trials
 Various attempts in trying to grow the cells with the 2D 
Bag A did not succeed 
• Picked the BR model 
that’s closest to 2000L 
SUB data, and also most 
consistent product quality 
data
Successful scale-up to 2000L SUB 
5
Confirmation of CPPs and obtaining
design space with DoE studies
4
Establishment of PAR & MAR
with univariate studies
3
Scale-down model qualification
based on GMP scale for PC studies
2
Identification of potential CPPs and
KPPs through risk analysis (FMEA)
1
Identification of CQAs that impact
product safety and efficacy S
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PPQ runs executed after completion of 
process characterization studies
• High level strategy shared with the FDA 
• Protocols drafted for upstream & 
downstream
• Batch records drafted based on PPQ 
protocols
• Detail sampling & in-process testing plans 
designed to support validation
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• Rolling BLA submission (with Orphan & Breakthrough status)
• Module 3 submission in parallel with Phase III trial
• Limited stability data from PPQ runs at time of submission
• Complete BLA submission once Phase III data was in.  
Additional stability data submitted to help set shelf life
Pre-License Inspection (PLI), BLA approval
• PLI conducted ~10 weeks after BLA submission
• Five inspectors, thirteen days total for the inspection
• Including two CMC reviewers
• PPQ run batch records, development reports, CPP & control 
strategies reviewed (NOR/MOR, IPCs etc)
• Continuous Process Verification (CPV) post BLA
